HISTONE DEACETYLASE INHIBITORS SENSITIZE CANCER CELLS TO EPIDERMAL GROWTH FACTOR INHIBITORS

摘要

Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.